Canakinumab
Indications
Canakinumab is used for:
Used in patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA).
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Canakinumab :
Mechanism of Action
In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1@) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1@, and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1@ activation. Canakinumab is a human monoclonal anti-human IL-1@ antibody of the IgG1/? isotype. Canakinumab binds to human IL-1@ and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1a or IL-1 receptor antagonist (IL-1ra).